重组酸性成纤维细胞生长因子可促进美国脊髓损伤协会损伤量表 A 型脊髓创伤患者的运动恢复并减少骨髓瘤。

IF 1.8 Q3 CLINICAL NEUROLOGY
Neurotrauma reports Pub Date : 2024-10-02 eCollection Date: 2024-01-01 DOI:10.1089/neur.2024.0063
Wan-Ya Chang, Wen-Cheng Huang, Yun-An Tsai, Lin-Hsue Yang, Yi-Tien Su, Shih-Fong Huang, Chiau-Li Huang, Ya-Hui Lee, Shu-Shong Hsu, Li-Yu Fay
{"title":"重组酸性成纤维细胞生长因子可促进美国脊髓损伤协会损伤量表 A 型脊髓创伤患者的运动恢复并减少骨髓瘤。","authors":"Wan-Ya Chang, Wen-Cheng Huang, Yun-An Tsai, Lin-Hsue Yang, Yi-Tien Su, Shih-Fong Huang, Chiau-Li Huang, Ya-Hui Lee, Shu-Shong Hsu, Li-Yu Fay","doi":"10.1089/neur.2024.0063","DOIUrl":null,"url":null,"abstract":"<p><p>This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment Scale (AIS) Grade A SCI who were randomly assigned to receive either a recombinant human aFGF or a placebo every 4 weeks for three doses. Participants underwent comprehensive evaluations of medical, neurological, and functional parameters at baseline and every 4 weeks after the first dose until the 48th week. The first dose was administered directly to the injury site during surgery within 6 weeks of the SCI, while the subsequent two doses were administered via lumbar puncture with a 4-week interval. The results revealed promising beneficial effects of aFGF on AIS Grade A SCI patients. The study report highlights aFGF's potential to expedite motor recovery in complete SCI patients and significantly increase the probability of a 10-point improvement when compared to the placebo group (odds ratio = 6.06, <i>p</i> = 0.0004). Furthermore, aFGF treatment exhibited a significant reduction (<i>p</i> < 0.01) in the incidence or exacerbation rate of myelomalacia, a known secondary complication following SCIs.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491575/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recombinant Acidic Fibroblast Growth Factor Facilitates Motor Recovery and Reduces Myelomalacia in Traumatic American Spinal Injury Association Impairment Scale A Spinal Cord Injured Patients.\",\"authors\":\"Wan-Ya Chang, Wen-Cheng Huang, Yun-An Tsai, Lin-Hsue Yang, Yi-Tien Su, Shih-Fong Huang, Chiau-Li Huang, Ya-Hui Lee, Shu-Shong Hsu, Li-Yu Fay\",\"doi\":\"10.1089/neur.2024.0063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment Scale (AIS) Grade A SCI who were randomly assigned to receive either a recombinant human aFGF or a placebo every 4 weeks for three doses. Participants underwent comprehensive evaluations of medical, neurological, and functional parameters at baseline and every 4 weeks after the first dose until the 48th week. The first dose was administered directly to the injury site during surgery within 6 weeks of the SCI, while the subsequent two doses were administered via lumbar puncture with a 4-week interval. The results revealed promising beneficial effects of aFGF on AIS Grade A SCI patients. The study report highlights aFGF's potential to expedite motor recovery in complete SCI patients and significantly increase the probability of a 10-point improvement when compared to the placebo group (odds ratio = 6.06, <i>p</i> = 0.0004). Furthermore, aFGF treatment exhibited a significant reduction (<i>p</i> < 0.01) in the incidence or exacerbation rate of myelomalacia, a known secondary complication following SCIs.</p>\",\"PeriodicalId\":74300,\"journal\":{\"name\":\"Neurotrauma reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491575/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurotrauma reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/neur.2024.0063\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurotrauma reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/neur.2024.0063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

这项研究旨在评估用酸性成纤维细胞生长因子(aFGF)治疗脊髓损伤(SCI)患者的潜在益处,酸性成纤维细胞生长因子是一种有效的神经营养因子,能保护神经元存活。这项研究涉及12名美国脊髓损伤协会损伤量表(AIS)A级SCI四肢瘫痪患者,他们被随机分配接受重组人aFGF或安慰剂,每4周一次,共3次。参试者在基线时接受医疗、神经和功能参数的综合评估,并在首次给药后每 4 周接受一次评估,直至第 48 周。第一剂在脊髓损伤后6周内的手术中直接注射到损伤部位,随后两剂通过腰椎穿刺注射,间隔4周。研究结果表明,aFGF 对 AIS A 级 SCI 患者有很好的疗效。研究报告强调,aFGF 有可能加快完全性 SCI 患者的运动恢复,与安慰剂组相比,aFGF 能显著提高患者运动能力提高 10 分的概率(几率比 = 6.06,p = 0.0004)。此外,aFGF 治疗还显著降低了脊髓空洞症的发生率或恶化率(p < 0.01),而脊髓空洞症是脊髓损伤后的一种已知继发性并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Recombinant Acidic Fibroblast Growth Factor Facilitates Motor Recovery and Reduces Myelomalacia in Traumatic American Spinal Injury Association Impairment Scale A Spinal Cord Injured Patients.

This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment Scale (AIS) Grade A SCI who were randomly assigned to receive either a recombinant human aFGF or a placebo every 4 weeks for three doses. Participants underwent comprehensive evaluations of medical, neurological, and functional parameters at baseline and every 4 weeks after the first dose until the 48th week. The first dose was administered directly to the injury site during surgery within 6 weeks of the SCI, while the subsequent two doses were administered via lumbar puncture with a 4-week interval. The results revealed promising beneficial effects of aFGF on AIS Grade A SCI patients. The study report highlights aFGF's potential to expedite motor recovery in complete SCI patients and significantly increase the probability of a 10-point improvement when compared to the placebo group (odds ratio = 6.06, p = 0.0004). Furthermore, aFGF treatment exhibited a significant reduction (p < 0.01) in the incidence or exacerbation rate of myelomalacia, a known secondary complication following SCIs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信